204 related articles for article (PubMed ID: 29600225)
1. Comparison of health-related quality of life with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil chemotherapy regimens as first-line systemic therapy in locally advanced inoperable or metastatic gastric or gastro-esophageal junction adenocarcinoma: A prospective study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Lokesh KN; Rajeev LK
South Asian J Cancer; 2018; 7(1):11-15. PubMed ID: 29600225
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey.
Teker F; Yilmaz B; Kemal Y; Kut E; Yucel I
Asian Pac J Cancer Prev; 2014; 15(16):6727-32. PubMed ID: 25169516
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
5. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting.
Kilickap S; Yalcin S; Ates O; Tekuzman G
Hepatogastroenterology; 2011; 58(105):208-12. PubMed ID: 21510316
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Roth AD; Fazio N; Stupp R; Falk S; Bernhard J; Saletti P; Köberle D; Borner MM; Rufibach K; Maibach R; Wernli M; Leslie M; Glynne-Jones R; Widmer L; Seymour M; de Braud F;
J Clin Oncol; 2007 Aug; 25(22):3217-23. PubMed ID: 17664469
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis.
Li B; Chen L; Luo HL; Yi FM; Wei YP; Zhang WX
World J Clin Cases; 2019 Mar; 7(5):600-615. PubMed ID: 30863759
[TBL] [Abstract][Full Text] [Related]
8. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
[TBL] [Abstract][Full Text] [Related]
9. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
10. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen.
Sendur MA; Ozdemir N; Özatlı T; Yazıcı O; Aksoy S; Ekinci AS; Yazılıtaş D; Günaydın Y; Oksuzoglu B; Benekli M; Zengin N
Med Oncol; 2014 Sep; 31(9):153. PubMed ID: 25099765
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF).
Sadighi S; Mohagheghi MA; Montazeri A; Sadighi Z
BMC Cancer; 2006 Dec; 6():274. PubMed ID: 17147808
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of FLOT regimen
Farrokhi P; Sadeghi A; Sharifi M; Riechelmann R; Moghaddas A
Res Pharm Sci; 2022 Dec; 17(6):621-634. PubMed ID: 36704436
[TBL] [Abstract][Full Text] [Related]
13. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
[TBL] [Abstract][Full Text] [Related]
14. Outcome evaluation of ECF, DCF, FOLFOX, and FLOT chemotherapy regimens as perioperative treatment in elderly patients with resectable gastric cancer; A retrospective comparative study.
Forouhari A; Moghaddas A; Darakhshandeh A
J Res Med Sci; 2023; 28():79. PubMed ID: 38292337
[TBL] [Abstract][Full Text] [Related]
15. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
[TBL] [Abstract][Full Text] [Related]
16. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
17. Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Lokesh KN; Rajeev LK
South Asian J Cancer; 2019; 8(2):85-87. PubMed ID: 31069184
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
Nishiwaki N; Noma K; Kunitomo T; Hashimoto M; Maeda N; Tanabe S; Sakurama K; Shirakawa Y; Fujiwara T
Esophagus; 2022 Oct; 19(4):626-638. PubMed ID: 35792947
[TBL] [Abstract][Full Text] [Related]
19. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
